Overview

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-31

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at least second-line treatment failure.

Phase:

PHASE3

Details

Lead Sponsor:

Hansoh BioMedical R&D Company

Treatments:

Docetaxel